Table 1.
Baseline demographic and clinical characteristics.
| Characteristics | Ca-CHD (n = 722) | Non-Ca-CHD (n = 540) | P-value |
|---|---|---|---|
| Age, years | 73.00 (66.00–77.00) | 71.00 (62.00–77.00) | 0.002 |
| Sex, male, % | 392 (54.3%) | 278 (51.5%) | 0.351 |
| KPS score | 82.49 (77.75–90.00) | 81.06 (77.41–90.00) | 0.275 |
| BMI, Kg/m2 | 23.12 (21.67–24.73) | 23.11 (21.48–24.64) | 0.526 |
| Cancer Type | |||
| Lung cancer | 216 (29.9%) | 228 (42.2%) | <0.001 |
| Prostate cancer | 83 (11.5%) | 112 (20.7%) | <0.001 |
| Ovarian cancer | 67 (9.3%) | 65 (12.0%) | 0.120 |
| Colorectal cancer | 59 (8.2%) | 25 (4.6%) | <0.001 |
| Gastric cancer | 36 (5.0%) | 14 (2.6%) | <0.001 |
| Cancer stage, n (%) | |||
| Ⅱ | 373 (51.7%) | 323 (59.8%) | 0.004 |
| Ⅲ | 21 (2.9%) | 6 (1.1%) | 0.025 |
| Ⅳ | 328 (45.4%) | 211 (39.1%) | 0.018 |
| Other complications, n (%) | |||
| Hypertension | 306 (42.4%) | 247 (45.7%) | 0.257 |
| Diabetes | 193 (26.7%) | 188 (34.8%) | 0.002 |
| Hyperlipemia | 38 (5.3%) | 25 (4.6%) | 0.703 |
| Hypercoagulability | 29 (4.0%) | 33 (6.1%) | 0.116 |
| Medication | |||
| Aspirin, clopidogrel, statin | 317 (43.9%) | 189 (35.0%) | <0.001 |
| Paclitaxel, carboplatin | 115 (15.9%) | 119 (22.0%) | <0.001 |
| Pemetrexed, cisplatin | 150 (20.8%) | 121 (22.4%) | <0.001 |
| Pembrolizumab | 44 (6.1%) | 64 (11.9%) | <0.001 |
| Cephalosporin, quinolone | 96 (13.3%) | 47 (8.7%) | <0.001 |